BriaCell Therapeutics Corp. (BCTX) stock: key figures, P/E, revenue and dividend

Health Care · Canada · ISIN CA10778Y3023

Price
3.31 USD
Market cap
28.90 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-212.82 %
Return on assets (ROA)
-148.03 %

BriaCell Therapeutics Corp. financials

Fiscal year20252026
Operating income-27.20 m USD-36.05 m USD
EBIT-26.64 m USD-35.93 m USD
Net income-26.31 m USD-34.90 m USD
Diluted EPS – continuing operations-62.19 USD-6.97 USD

Full history since 2006, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.